- 全部删除
- 您的购物车当前为空
Balixafortide TFA (POL6326 TFA) is a selective, well-tolerated peptidic CXCR4 antagonist (IC50 < 10 nM). It shows 1000-fold selective for CXCR4 than a large panel of receptors including CXCR7. Balixafortide TFA blocks β-arrestin recruitment and calcium flux (IC50s < 10 nM).
Balixafortide TFA (POL6326 TFA) is a selective, well-tolerated peptidic CXCR4 antagonist (IC50 < 10 nM). It shows 1000-fold selective for CXCR4 than a large panel of receptors including CXCR7. Balixafortide TFA blocks β-arrestin recruitment and calcium flux (IC50s < 10 nM).
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
5 mg | ¥ 1,480 | 待询 | |
25 mg | ¥ 5,305 | 待询 | |
50 mg | ¥ 8,960 | 待询 | |
100 mg | 待询 | 待询 | |
200 mg | 待询 | 待询 |
Balixafortide TFA (1051366-32-5 free base) 相关产品
产品描述 | Balixafortide TFA (POL6326 TFA) is a selective, well-tolerated peptidic CXCR4 antagonist (IC50 < 10 nM). It shows 1000-fold selective for CXCR4 than a large panel of receptors including CXCR7. Balixafortide TFA blocks β-arrestin recruitment and calcium flux (IC50s < 10 nM). |
靶点活性 | CXCR4:10 nM |
体外活性 | Balixafortide efficiently blocks SDF-1 dependent chemotaxis of MDA MB 231 breast cancer cells (IC50 < 20 nM), Namalwa and Jurkat cells (IC50 < 10 nM). Balixafortide potently inhibits pERK / pAKT signaling in the lymphoma lines Jurkat (IC50 < 400 nM) and Namalwa (IC50< 200 nM) [1]. |
体内活性 | Balixafortide is optimized for favorable mouse absorption, distribution, metabolism, and excretion (ADME) properties with balanced plasma protein binding, microsomal stability, and greater plasma. |
别名 | POL6326 TFA, Balixafortide TFA |
分子量 | 1896.05 |
分子式 | C82H113N22F3O23S2 |
密度 | 1.31g/cm3 |
Sequence | Cyclo(L-alanyl-L-cysteinyl-L-seryl-L-alanyl-D-prolyl-(2S)-2,4-diaminobutanoyl-L-arginyl-L-tyrosyl-L-cysteinyl-L-tyrosyl-L-glutaminyl-L-lysyl-D-prolyl-L-prolyl-L-tyrosyl-L-histidyl), cyclic (2->9)-disulfide |
存储 | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
评论内容